hero section gradient
18 handpicked stocks

Riding The New Tech IPO Wave

Figma's blockbuster IPO has shattered a multi-year drought in major tech listings, signaling renewed investor appetite for high-growth software companies. This event may trigger a wave of public offerings from other venture-backed "unicorns," creating opportunities across the tech ecosystem.

Author avatar

Han Tan | Market Analyst

Published on August 1

Your Basket's Financial Footprint

Aggregated market capitalisation breakdown for the basket 'Riding The New Tech IPO Wave'.

Key Takeaways for Investors:
  • Large-cap dominance tends to reduce volatility, offering more stable returns and closer tracking of broad market trends.
  • Suitable as a core holding to provide steady market exposure rather than a speculative, high-growth allocation.
  • Expect steady long-term appreciation rather than rapid gains; upside may be moderate given large-cap weighting.
Total Market Cap
  • TEAM: $44.41B

  • ADBE: $149.67B

  • SNOW: $83.86B

  • Other

About This Group of Stocks

1

Our Expert Thinking

Figma's successful IPO has broken a multi-year drought in major tech listings, potentially signalling a turning point for the technology sector. This renewed investor confidence could create a more favourable environment for other venture-backed unicorns to go public, particularly in the software-as-a-service space.

2

What You Need to Know

This collection focuses on high-growth tech companies that could benefit from the revived IPO market sentiment. It includes a mix of recently public firms and established software players that reflect this broader shift in investor appetite for technology equities.

3

Why These Stocks

These stocks were handpicked by professional analysts to capture potential upside from renewed market activity in the tech sector. They represent companies positioned to benefit from the reopening of the technology IPO market and subsequent value creation opportunities.

Why You'll Want to Watch These Stocks

🚀

IPO Market Revival

Figma's blockbuster debut has broken years of IPO drought, potentially opening the floodgates for other high-growth tech companies to go public.

💎

Unicorn Opportunity Window

Venture-backed unicorns may now accelerate their public offerings, creating fresh investment opportunities in previously private companies.

📈

Renewed Investor Confidence

The strong market reception signals a shift in sentiment towards tech equities, potentially benefiting established players in this space.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Automotive Semiconductor Gap Explained | Market Shift

Automotive Semiconductor Gap Explained | Market Shift

A major semiconductor supplier's export ban from China is halting vehicle production, creating a potential opening for other chip manufacturers. This theme identifies alternative semiconductor companies poised to fill the critical supply gap for the automotive industry.

Brazil Smart Farming Tech Investment Basket 2025

Brazil Smart Farming Tech Investment Basket 2025

As Brazil solidifies its role as a global agricultural leader, advanced technologies are unlocking new levels of productivity and sustainability for its farms. This basket offers exposure to the US and EU-listed companies providing the essential hardware, software, and data analytics driving this transformation.

Weight-Loss Drug M&A: Valuation Risk Concerns

Weight-Loss Drug M&A: Valuation Risk Concerns

Novo Nordisk's superior bid for Metsera has ignited a bidding war with Pfizer, highlighting the intense M&A activity in the obesity drug market. This theme focuses on other biotech companies with promising weight-loss therapies that could become the next acquisition targets.

Frequently Asked Questions